Latest Information Update: 05 Feb 2016
At a glance
- Originator Changchun Huayang High-tech
- Class Aminoacridines
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 01 Jun 2011 Phase-II clinical trials in Alzheimer's disease in China (PO)
- 31 Dec 2010 Phase-I clinical trials in Alzheimer's disease in China (PO)